bispecific antibody AGEN1223
Term · Oncology and biomedicine · MLC-T-ONC-012035
A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens co-expressed specifically on tumor-infiltrating regulatory T cells (Tregs), with potential immunomodulating and antineoplastic activities. Upon administration, AGEN1223 targets and binds to the two antigens co-expressed specifically on tumor-infiltrating Tregs. This leads to the selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME), while sparing peripheral Tregs and effector T cells, enhancing the overall antitumor response. AGEN1223 may also co-stimulate antigen-specific effector T cells, resulting in tumor cell death.
| Identifier | MLC-T-ONC-012035 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | AGEN-1223 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012035",
"term": "bispecific antibody AGEN1223",
"field": "Oncology and biomedicine",
"definition": "A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens co-expressed specifically on tumor-infiltrating regulatory T cells (Tregs), with potential immunomodulating and antineoplastic activities. Upon administration, AGEN1223 targets and binds to the two antigens co-expressed specifically on tumor-infiltrating Tregs. This leads to the selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME), while sparing peripheral Tregs and effector T cells, enhancing the overall antitumor response. AGEN1223 may also co-stimulate antigen-specific effector T cells, resulting in tumor cell death.",
"synonyms": [
"AGEN-1223"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/bispecific-antibody-agen1223/"
}
Record 3,612 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.